<?xml version='1.0' encoding='utf-8'?>
<document id="9476144"><sentence text="P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound."><entity charOffset="133-142" id="DDI-PubMed.9476144.s1.e0" text="talinolol" /></sentence><sentence text="Among the different application routes peroral administration remains the one most widely used" /><sentence text=" Hence, mechanisms affecting p" /><sentence text="o" /><sentence text=" bioavailability are of particular interest, also in drug development" /><sentence text=" In recent years, intestinal drug secretion mediated by the multi-drug resistance gene product P-glycoprotein (Pgp) has been discovered as a possible mechanism of low and erratic bioavailability" /><sentence text=" Due to the saturability of this process, a dose-dependent apparent oral clearance may be observed which decreases upon increasing dose" /><sentence text=" However, in vivo intestinal secretion might be revealed only in the lower or subtherapeutic dose range" /><sentence text=" In permeability studies with Caco-2 cell monolayers, the MDR-reversing agent verapamil inhibits secretion of P-glycoprotein substrates and, hence, increases apical-to-basolateral permeability" /><sentence text=" The aim of the rat studies with talinolol presented here was to test the relevance of the intestinal secretion process as well as the extent of inhibition by verapamil in ex vivo, in situ, and in vivo talinolol/verapamil drug-drug interaction studies"><entity charOffset="33-42" id="DDI-PubMed.9476144.s10.e0" text="talinolol" /></sentence><sentence text=" Intestinal secretion of talinolol was detected indirectly in ex vivo studies via transport inhibition with verapamil and directly in in situ intestinal perfusions in rats following a talinolol i"><entity charOffset="25-34" id="DDI-PubMed.9476144.s11.e0" text="talinolol" /><entity charOffset="184-193" id="DDI-PubMed.9476144.s11.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.9476144.s11.e0" e2="DDI-PubMed.9476144.s11.e0" /><pair ddi="false" e1="DDI-PubMed.9476144.s11.e0" e2="DDI-PubMed.9476144.s11.e1" /></sentence><sentence text="v" /><sentence text=" bolus" /><sentence text=" Both i" /><sentence text="v" /><sentence text=" and p" /><sentence text="o" /><sentence text=" verapamil appear to affect the concentration-time profiles of talinolol"><entity charOffset="1-10" id="DDI-PubMed.9476144.s18.e0" text="verapamil" /><entity charOffset="63-72" id="DDI-PubMed.9476144.s18.e1" text="talinolol" /><pair ddi="false" e1="DDI-PubMed.9476144.s18.e0" e2="DDI-PubMed.9476144.s18.e0" /><pair ddi="false" e1="DDI-PubMed.9476144.s18.e0" e2="DDI-PubMed.9476144.s18.e1" /></sentence><sentence text=" Relevant observations with respect to drug absorption are the decreased apparent oral clearance upon verapamil coadministration as well as the decreased tmax and mean absorption times at high verapamil doses" /><sentence text=" Talinolol may be regarded as a potential model compound for mechanistic studies on Pgp interactions, including permeability as well as binding studies and the involvement of transporters other than Pgp"><entity charOffset="1-10" id="DDI-PubMed.9476144.s20.e0" text="Talinolol" /></sentence><sentence text="" /></document>